Actively Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Led by Verrica Pharmaceuticals Inc. · Updated on 2026-01-21
300
Participants Needed
6
Research Sites
75 weeks
Total Duration
On this page
Sponsors
V
Verrica Pharmaceuticals Inc.
Lead Sponsor
C
Canfield Scientific Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.
CONDITIONS
Official Title
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients 2 years of age or older
- Immunocompetent individuals
- Have at least one treatable common wart (verruca vulgaris) of any size and height located anywhere except eyes, lips, oral cavity, nasal cavity, inside ears, soles of feet, under fingernails or toenails, or anogenital area
- No systemic or skin disorder that might affect study results or increase risk of adverse events
- Agree to avoid swimming, bathing, or prolonged immersion in water until study drug is removed after treatment
- Ability or parent/guardian ability to follow study instructions and complete study requirements
- Agree not to use other wart-removing products during the study except as allowed
- Provide written informed consent or assent, or parent/guardian consent if under legal age
- Provide written authorization for use and disclosure of protected health information
- Agree to optional wart photography at selected visits
You will not qualify if you...
- Unable to cooperate with study requirements or visits
- Have warts in allowed areas that you or your parent/guardian or investigator do not want to treat
- Have plantar warts, external genital warts, subungual warts, or warts within 10 mm of mucosal surfaces
- Are systemically immunosuppressed or have taken systemic immunosuppressive medications within 30 days before enrollment or plan to during study
- Have chronic or acute medical conditions that may interfere with study or increase risk (eg, HIV, lupus, viral hepatitis, uncontrolled diabetes)
- Have received any treatment for common warts within 90 days before treatment start
- Have more warts or wart area than can be covered by two study applicators
- Received any investigational product for common warts within 30 days before treatment
- Have epidermodysplasia verruciformis
- Have active malignancy or undergoing treatment for malignancy
- Have medical, psychiatric, or emotional conditions that could affect safety or data quality
- History of hypersensitivity or unusual reaction to study drug or related compounds
- Conditions or situations interfering with participation (eg, recent hospitalization for acute or chronic conditions including substance abuse)
- Are sexually active or may become sexually active and unwilling to use effective birth control; females of childbearing potential must have negative pregnancy test before treatment
- Are pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Florida Center for Dermatology, P.A.
Saint Augustine, Florida, United States, 32080
Actively Recruiting
2
The Indiana Clinical Trials Center, PC
Plainfield, Indiana, United States, 46168
Actively Recruiting
3
Anne Arundel Dermatology, PA dba Maryland Dermatology Laser Skin & Vein
Hunt Valley, Maryland, United States, 31030
Actively Recruiting
4
Tennessee Clinical Research Center, Inc.
Nashville, Tennessee, United States, 37215
Actively Recruiting
5
The University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030
Not Yet Recruiting
6
Texas Dermatology and Laser Specialists
San Antonio, Texas, United States, 78218
Actively Recruiting
Research Team
P
Project Manager
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here